AstraZeneca's drug Tagrisso gets China nod for early lung cancer

AstraZeneca's drug Tagrisso gets China nod for early lung cancer China's National Medical Products Administration (NMPA) approved Tagrisso as an adjuvant therapy for patients with early-stage lung cancer who have a mutation of the EGFR gene, AstraZeneca said. https://ift.tt/eA8V8J